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A b s t r a c t
Background: Epigallocatechin-3-gallate (EGCG), which is the principal component of green tea, has been shown to prevent 
atherosclerosis. However, the effect of EGCG on atherosclerotic plaque stability remains unknown. 
Aim: This study aimed to assess whether EGCG can enhance atherosclerotic plaque stability and to investigate the underlying 
mechanisms. 
Methods: Apolipoprotein E-deficient mice fed a high-fat diet were injected intraperitoneally with EGCG (10 mg/kg) for 
16 weeks. Cross sections of the brachiocephalic arteries were stained with haematoxylin and eosin for morphometric analyses 
or Masson’s trichrome for collagen content analyses. Immunohistochemistry was performed to evaluate the percentage of 
macrophages and smooth muscle cells (SMCs). Protein expression and matrix metalloproteinase (MMP) activity were assayed 
by Western blot and gelatin zymography, respectively. Serum inflammatory cytokine levels were quantified by enzyme-linked 
immunosorbent assays. 
Results: After 16 weeks of feeding the high-fat diet, there were clear atherosclerotic lesions in the proximal brachiocephalic 
artery segments according to HE staining. EGCG treatment significantly increased the thickness of the fibrous cap. In the 
atherosclerotic plaques of the EGCG group, the relative macrophage content was decreased, whereas the relative SMC 
and collagen contents were increased. The expression levels of MMP-2, MMP-9, and extracellular matrix metalloproteinase 
inducer (EMMPRIN) were significantly decreased by EGCG treatment. In addition, EGCG treatment decreased the circulat-
ing tumour necrosis factor-α, interleukin-6, monocyte chemoattractant protein-1, and interferon-γ levels in apolipoprotein 
E-deficient mice. 
Conclusions: EGCG promotes atherosclerotic lesion stability in apolipoprotein E-deficient mice. Potentially, these effects are 
mediated through the inhibition of inflammatory cytokine, MMPs and EMMPRIN expression.
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INTRODUCTION
Coronary artery disease (CAD) is the leading global cause of 
death, morbidity, and disability. Among patients with CAD, 
acute coronary syndrome (ACS) is responsible for significant 
patient morbidity and mortality and is a frequent cause of 
hospital admissions. ACS refers to a range of acute myocardial 
ischaemic states, which include ST-segment elevation myo-
cardial infarction (STEMI), non-STEMI, and unstable angina. 
Numerous reports have shown that coronary thrombosis, which 
is the immediate cause of ACS, results from vulnerable plaque 
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rupture. Therefore, it is critical to improve atherosclerotic 
plaque stability in the treatment of ACS. Vulnerable plaques 
are characterised by a large necrotic core and a thin fibrous 
cap (< 65 µm) with macrophage and lymphocyte infiltration. 
There are few or no smooth muscle cells (SMCs) within the 
fibrous cap [1]. Growing evidence indicates that inflammation 
and matrix degradation by matrix metalloproteinases (MMPs) 
are the primary causes of atherosclerotic plaque instability [2]. 
Currently, the most appropriate therapeutic approach for 
preventing acute adverse coronary events is to modify the 
atherosclerotic plaque composition rather than bypass the le-
sion or reduce stenosis by using mechanical interventions [3].
Green tea is a popular drink around the world. Regular 
consumption of green tea has been suggested to protect 
against a variety of diseases, including cancer, stroke, and 
cardiovascular diseases [4–6]. The beneficial effects of green 
tea are attributed to its abundant and biologically active 
polyphenols. Catechins, the major constituents of green tea 
polyphenols, mainly comprise (–)-epigallocatechin-3-gallate 
(EGCG), (–)-epicatechin (EC), (–)-epigallocatechin (EGC), and 
(–)-epicatechin-3-gallate (ECG). Of these, EGCG is the most 
abundant catechin in green tea [6]. Numerous reports have 
demonstrated that the green tea polyphenol EGCG is a potent 
antioxidant that plays an important role in inhibiting inflam-
mation [7, 8]. In our previous study, we showed that EGCG 
suppressed tumour necrosis factor-α (TNF-α)-induced mono-
cyte chemoattractant protein-1 (MCP-1) expression in human 
umbilical vein endothelial cells (HUVECs) [9]. Additionally, 
EGCG inhibits the expression and gelatinolytic activity of MMPs 
in macrophages and SMCs [10, 11]. Furthermore, we showed 
that EGCG inhibited the upregulation of extracellular matrix 
metalloproteinase inducer (EMMPRIN) and MMP-9 expression 
in PMA-induced macrophages through 67LR [12]. These data all 
suggest that EGCG can enhance atherosclerotic plaque stability. 
Chyu et al. [13] found that EGCG prevented the forma-
tion of atherosclerotic lesions. However, the effect of green 
tea polyphenols on atherosclerotic plaque stability remains 
unknown. Hence, in the present study, we aimed to elucidate 
the effect and underlying molecular mechanisms of the green 




Apolipoprotein E-deficient mice fed a high-fat diet were used 
to evaluate atherosclerotic plaque stability [14]. Thirty male 
apolipoprotein E-deficient mice (age: eight weeks; weight: 
18–20 g) were obtained from the Model Animal Research Cen-
tre of Nanjing University (Nanjing, Jiangsu, China). All animals 
were maintained on a light/dark (12/12 h) cycle and at constant 
room temperature. The mice were fed a high-fat diet that con-
tained 21% fat and 0.15% cholesterol (Medicine, Yangzhou, 
Jiangsu, China). The apolipoprotein E-deficient mice were 
randomly divided into a control group (n = 15) and an EGCG 
(Sigma, St Louis, MO, USA) group (n = 15). For 16 weeks, 
EGCG (10 mg/kg body weight/day, five days/week) [13] or 0.9% 
saline was injected intraperitoneally into the apolipoprotein 
E-deficient mice. Then, the animals were anaesthetised, and 
the blood, aorta, and brachiocephalic arteries were harvested. 
All the procedures were conducted following the regulations 
of the National Institute of Health Guide for the Care and 
Use of Laboratory Animals and approved by the Experimental 
Animal Ethics Committee of Nanjing Medical University (ethic 
approval no: IACUC-1601044, date: 2016-03).
Analysis of lipid and inflammatory cytokine levels
Blood samples were obtained from the retro-orbital plexus 
after the mice were anaesthetised. Serum lipid profiles were 
determined using an enzymatic assay (Roche, Shanghai, China) 
according to the manufacturer’s instructions. Circulating levels 
of MCP-1, interleukin-6 (IL-6), TNF-α, and interferon-γ (IFN-γ) 
were measured using ELISA assay kits (CUSABIO, Wuhan, 
China) in accordance with the manufacturer’s instructions.
Immunohistochemistry and histology
Brachiocephalic arteries were harvested and embedded in 
paraffin. Cross sections (4 µm) were stained with haematoxy-
lin and eosin (HE) to evaluate the plaque morphologies and 
with Masson’s trichrome to evaluate the collagen content in 
the plaques. Immunohistochemical staining was performed 
using an anti-Mac-2 mouse macrophage antibody (Abcam, 
Cambridge, UK) and an anti-α smooth muscle actin antibody 
(α-SMA, Sigma, St. Louis, MO, USA). The sections were im-
aged under a Nikon DS-Fi1 microscope (Nikon Corporation, 
Sendai, Japan). The integrated optical densities of the different 
indicators were analysed using Image-Pro Plus 6.0 (Media 
Cybernetics, Bethesda, MD, USA).
RNA isolation, cDNA synthesis, and quantitative 
real-time polymerase chain reaction 
Total RNA was extracted from aortic tissues with Trizol 
reagent (Invitrogen, Carlsbad, CA, USA) and reverse-tran-
scribed into cDNA with the Reverse Transcription Kit 
(Takara, Dalian, Liaoning, China). Quantitative real-time 
polymerase chain reaction was performed using the ABI 
7900 Sequence Detection System (Applied Biosystems, 
Foster, CA, USA) with Power SYBR green PCR Master Mix 
(Applied Biosystems, Foster, CA, USA) according to the 
manufacturer’s instructions. The primer sequences were as 
follows: MMP-2, Sense: 5’-GTTGCAACCTCTTTGTGCTG-3’, 
Antisense: 5’-TGATCTGGTTCTTGTCCCACT-3’; MMP-9, 
Sense: 5’-TCAAGGATTGCTCAGAGATT-3’, Antisense: 
5’-GCAACCACAGTGAGTGAGTT-3’; EMMPRIN, Sense: 
5’-CAGAAAACCCACCTGGAAGA-3’, Antisense: 5’-ATAAAC-
CCCTAAGGAATGGA-3’. The expression levels of target 
genes were normalised against the glyceraldehyde 3-phos-
phate dehydrogenase (GAPDH) level; the 2–ΔΔCt method was 
used to calculate gene expression change.
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Protein isolation and Western blot analyses
Protein isolation from the aorta and Western blot analyses were 
performed as previously described [12]. Briefly, equal amounts 
of protein were electrophoresed on 12% polyacrylamide 
gels and transferred onto polyvinylidene difluoride mem-
branes. The membranes were blocked for 2 h with 5% bovine 
serum albumin in Tris-buffered saline and Tween-20 and incu-
bated with primary antibodies for MMP-2, MMP-9, EMMPRIN 
(Abcam, Cambridge, UK), and GAPDH (Cell Signalling Tech-
nology, Boston, MA, USA) overnight at 4°C. The membranes 
were then incubated with horseradish peroxidase-labelled 
secondary antibodies (Santa Cruz, Dallas, TX, USA) for 1 h at 
room temperature. All signals were detected using a ChemiDoc 
XRS Imaging System (Bio-Rad, Hercules, CA, USA).
Gelatin zymography
MMP-2 and MMP-9 activities were determined by gelatin 
zymography [12]. The aorta protein supernatants were elec-
trophoresed on 10% polyacrylamide gels containing 1 mg/mL 
gelatin. After washing twice for 15 min with 2.5% Triton 
X-100 at 37oC, the gels were incubated in a developing buffer 
(10 mM Tris base, 40 mM Tris-HCl, 200 mM NaCl, 10 mM 
CaCl2, and 0.02% Brij 35) at 37oC for 11 h. Finally, the gels 
were stained with 0.5% Coomassie Blue R-250 for 2 h and 
then treated with a destaining buffer (50% methanol, 10% 
glacial acetic acid, and 40% water). Proteolysis was detected 
as a clear white band against a blue background. The MMP 
activity was quantified by using Image J (National Institutes 
of Health, Bethesda, MD, USA).
Statistical analysis
The data were analysed using SPSS version 17.0 (SPSS Inc., 
Chicago, IL, USA). All values are shown as the mean ± stand-
ard error of mean. Statistical significance was determined 
by Student t test. P-values < 0.05 were considered statisti-
cally significant.
RESULTS
Effects of EGCG on body weight  
and plasma lipid profile
To investigate the functional role of EGCG in atherosclerotic 
plaque stability, EGCG or 0.9% saline was administered 
to mice fed a high-fat diet for 16 weeks. We found no 
significant differences in the body weights after EGCG 
treatment. Similarly, there were no differences in the total 
cholesterol, triglyceride, low-density lipoprotein cholesterol 
(LDL-C) or high-density lipoprotein cholesterol (HDL-C) 
levels (Table 1). 
Effects of EGCG on atherosclerotic  
plaque size and stability
After 16 weeks of high-fat diet feeding, atherosclerotic plaques 
were observed in the segment of proximal brachiocephalic 
arteries with HE staining (Fig. 1). The size of atherosclerotic 
plaques decreased significantly in the EGCG group (Fig. 2C). 
To determine whether EGCG enhanced atherosclerotic plaque 
stability in apolipoprotein E-deficient mice fed a high-fat diet, 
we compared the atherosclerotic plaque compositions in mice 
from the two groups. The relative collagen, SMC, and mac-
rophage contents were detected by Masson’s trichrome and 
immunohistochemical staining. We found that the collagen 
and SMC contents were significantly greater in the EGCG 
group than in the 0.9% saline group (Fig. 2B, E; 3B, D). The 
macrophage content was significantly lower in the EGCG 
group than in the 0.9% saline group (Fig. 3A, C). Moreover, 
EGCG treatment significantly increased the thickness of the 
fibrous cap (Fig. 2A, D). These results indicated that EGCG 
treatment enhanced atherosclerotic plaque stability. 
Effects of EGCG on circulating  
inflammatory cytokine levels
Numerous reports have demonstrated that inflammatory cy-
tokines play a pivotal role in the complex processes of athero-
genesis and plaque destabilisation. To investigate the effects 
of EGCG on circulating inflammatory cytokines, the levels of 
the latter were measured with the use of ELISAs. MCP-1 and 
IL-6 levels were significantly lower in the EGCG group than 
in the 0.9% saline group. Moreover, EGCG treatment de-
creased serum TNF-α and IFN-γ levels by 53.5% and 39.7%, 
respectively (Fig. 4). These data showed that EGCG treat-
ment inhibited the inflammatory responses in apolipoprotein 
E-deficient mice fed a high-fat diet. 
Effects of EGCG on MMP-2, MMP-9,  
and EMMPRIN expression
Given that MMPs play a crucial role in the pathogenesis of 
vulnerable plaques, we examined whether EGCG regulates the 
expression levels of MMP-2 and MMP-9. The results showed 
that compared to 0.9% saline treatment, EGCG treatment 
significantly decreased MMP-2 and MMP-9 expression and 
activity levels (Fig. 5). Furthermore, we investigated the ef-
fects of EGCG on the expression of EMMPRIN, which induces 
MMP-2 and MMP-9 expression [15]. The results showed that 
Table 1. Effects of epigallocatechin-3-gallate (EGCG) on body 
weight and lipid concentrations
Control group EGCG group
Body weight [g] 31.7 ± 4.08 29.9 ± 4.36
Total cholesterol [mM] 17.44 ± 2.13 16.89 ± 2.27
Triglyceride [mM] 2.67 ± 0.58 2.39 ± 0.62
LDL-C [mM] 7.84 ± 1.34 7.66 ± 1.11
HDL-C [mM] 1.63 ± 0.33 1.87 ± 0.41
The differences between the EGCG and control groups were not signifi-
cant (p > 0.05). All values are shown as the mean ± standard error of 
mean (n = 7). HDL-C — high-density lipoprotein cholesterol; LDL-C — 
low-density lipoprotein cholesterol
www.kardiologiapolska.pl
Epigallocatechin-3-gallate increases atherosclerotic plaque stability
1265
Figure 1. The formation of atherosclerotic plaques in the proximal brachiocephalic arteries. After 16 weeks of high-fat diet  
feeding, atherosclerotic plaques were observed in the segment of arteries with haematoxylin and eosin staining (arrows)
Figure 2. Effect of epigallocatechin-3-gallate (EGCG) on the plaque size, fibrous cap thickness, and collagen content of athero-
sclerotic plaques in the proximal brachiocephalic arteries. Representative photographs showing haematoxylin and eosin (HE) (A) 
and Masson’s trichrome (B) staining of the arteries. C. Quantitative analysis of the results in panel A. D. Quantitative analysis of 
the results in panel A. E. Quantitative analysis of the results in panel B. All values are shown as the mean ± standard error of 
mean (n = 7; **p < 0.01 vs. control group; ***p < 0.001 vs. control group)
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Figure 3. Effect of epigallocatechin-3-gallate (EGCG) on the macrophage and smooth muscle cell contents of atherosclerotic 
plaques in the proximal brachiocephalic arteries. Representative photographs showing anti-Mac-2 (A) and anti-α smooth muscle 
actin antibody (α-SMA) (B) staining of the arteries. C. Quantitative analysis of the results in panel A. D. Quantitative analysis of 
the results in panel B. All values are shown as the mean ± standard error of mean (n = 7; **p < 0.01 vs. control group)
Figure 4. Effect of epigallocatechin-3-gallate (EGCG) on circulating inflammatory cytokine concentrations. Serum monocyte che-
moattractant protein-1 (MCP-1, A), tumour necrosis factor-α (TNF-α; B), interleukin-6 (IL-6; C), and interferon-γ (IFN- γ; D) levels 
were significantly reduced by EGCG. All values are shown as the mean ± standard error of mean (n = 7; *p < 0.05 vs. control 
group; **p < 001 vs. control group; ***p < 0.001 vs. control group)
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EMMPRIN mRNA and protein expression levels were mark-
edly reduced after EGCG treatment (Fig. 5). This suggests that 
EGCG increases atherosclerotic plaque stability by suppressing 
MMP-2, MMP-9, and EMMPRIN expression. 
DISCUSSION
It is common knowledge that coronary atherosclerotic plaque 
development is the underlying condition for ischaemic heart 
disease. On its own, atherosclerosis is a relatively benign dis-
ease. In contrast, atherothrombosis caused by atherosclerotic 
plaque rupture may lead to life-threatening ACS. The risk of 
plaque rupture depends more on the plaque composition 
and stability than on the severity of stenosis. In this study, 
the green tea polyphenol EGCG, which is the most abundant 
catechin in green tea, improved atherosclerotic plaque sta-
bility in apolipoprotein E-deficient mice fed a high-fat diet. 
Furthermore, this effect was mediated through the inhibition 
of inflammatory responses as well as MMP-2, MMP-9, and 
EMMPRIN expressions. To the best of our knowledge, the 
present study is the first to evaluate the effects of a green 
tea polyphenol on the stability of atherosclerotic plaques.
Our epidemiological studies have demonstrated that green 
tea consumption reduces the risk of CAD [16, 17]. In addition, 
the consumption of green tea has been associated with a lower 
risk of acute myocardial infarction (AMI) [18]. Furthermore, 
EGCG can prevent the formation of atherosclerotic plaques [13]. 
However, the effect of green tea polyphenols on atherosclerotic 
plaque stability remains unknown. As previously mentioned, 
the lipid core size, fibrous cap thickness, plaque cell composi-
tion, and local MMP expression levels are key determinants of 
Figure 5. Effect of epigallocatechin-3-gallate (EGCG) on the expression of matrix metalloproteinase (MMP)-2, MMP-9 and 
extracellular matrix metalloproteinase inducer (EMMPRIN) in atherosclerotic plaques. A. Representative Western blots for 
MMP-2, MMP-9, and EMMPRIN; B. Representative gelatin zymography images showing MMP-2 and MMP-9 activity; C. Relative 
mRNA expression of MMP-2, MMP-9, and EMMPIRN; D. Quantitative analysis of the results in panel A; E. Quantitative analy-
sis of the results in panel B. All values are shown as the mean ± standard error of mean (n = 7; *p < 0.05 vs. control group; 
**p < 0.01 vs. control group); GAPDH — glyceraldehyde 3-phosphate dehydrogenase
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plaque stability. Collagen is the primary structural component 
of the fibrous cap of atherosclerotic plaques [1]. Accumulating 
evidence has emphasised the critical role of collagen synthesis 
and breakdown in the maintenance of fibrous cap strength and 
integrity. The amount and organisation of matrix collagen have 
been widely used as indirect indicators of plaque stability [19]. In 
this study, EGCG treatment significantly increased the thickness 
of the fibrous cap. Moreover, collagen content in the plaques 
was remarkably increased by EGCG treatment. Vascular SMCs 
are the only cells capable of synthesising extracellular matrix 
collagen in atherosclerotic plaques. Therefore, we also used im-
munohistochemical staining to determine the composition of cell 
types present in atherosclerotic plaques. The results showed that 
the relative macrophage content decreased, whereas the relative 
SMC content increased, in the atherosclerotic plaques of the 
EGCG group. These findings indicate that EGCG administration 
can promote atherosclerotic plaque stability in apolipoprotein 
E-deficient mice fed a high-fat diet. 
MMPs are a group of similar-structured proteases involved 
in the degradation of collagen and most other extracellular 
matrix components [20]. Therefore, the overexpression of 
MMPs can promote atherosclerotic plaque instability [2]. 
Numerous reports have indicated that MMP-2 and MMP-9, 
also known as gelatinases, participate in plaque destabilisation 
and rupture [21, 22]. In the present study, protein expression 
and activity levels of MMP-2 and MMP-9 were determined 
by Western blot and gelatin zymography, respectively. The 
results showed that EGCG treatment significantly inhibited 
the protein expression and activity levels of MMP-2 and 
MMP-9. EMMPRIN, also called CD147 or basigin, has been 
reported to induce the production of various MMPs in tumour 
studies [23]. Similarly, EMMPRIN has been shown to regulate 
MMP-2 and MMP-9 expressions in monocytes, macrophages, 
and SMCs [20]. In recent years, a growing body of evidence has 
suggested that EMMPRIN plays an important role in the complex 
processes of atherosclerotic plaque rupture and atherothrombosis 
[24]. Previously, we found that EGCG significantly suppressed 
the expression of EMMPRIN and MMP-9 in a dose-dependent 
manner in PMA-induced macrophages [12]. Our current data 
our data showed that protein levels of EMMPRIN were markedly 
reduced after EGCG treatment in apolipoprotein E-deficient mice 
fed a high-fat diet. Taken together, these results suggest that EGCG 
improves atherosclerotic plaque stability by inhibiting MMP-2, 
MMP-9, and EMMPRIN expressions.
Furthermore, MCP-1, IL-6, and TNF-α have been shown 
to upregulate the expression of MMPs. IFN-γ was found to 
inhibit collagen synthesis in human vascular SMCs and trigger 
apoptosis in vascular SMCs [2]. Our previous study showed 
that EGCG suppressed TNF-α-induced MCP-1 expression in 
HUVECs via inhibiting the activation of the nuclear factor-
κB [9]. In addition, in vivo studies showed that EGCG could 
inhibit the production of MCP-1, TNF-α, IL-6, and IFN-γ 
[25]. To investigate the effects of EGCG on MCP-1, TNF-α, 
IL-6, and IFN-γ expression, the levels of these circulating 
inflammatory cytokines were measured by ELISA. The results 
showed that serum MCP-1, TNF-α, IL-6, and IFN-γ levels 
were significantly reduced by EGCG. These findings indicate 
that the administration of EGCG increases atherosclerotic 
plaque stability through suppressing inflammatory responses.
In our study, we found that there were no differences in the 
total cholesterol, triglyceride, LDL-C, or HDL-C levels between 
the EGCG (10 mg/kg/day) and control groups. Consistent with 
our findings, Chyu et al. [13] found that EGCG (10 mg/kg/day) 
reduced cuff-induced evolving atherosclerotic plaque size, but 
no difference was observed in total cholesterol level. How-
ever, other studies found that supplementation with EGCG 
(40 mg/kg/day, 100 mg/kg/day) dramatically increased HDL-C 
levels and decreased total cholesterol and LDL-C levels. These 
disparate findings may be explained by different doses of EGCG 
used. Our results suggest that EGCG enhances atherosclerotic 
plaque stability independently of circulating lipid levels [26, 27]. 
In conclusion, we reported for the first time that the green 
tea polyphenol EGCG could enhance atherosclerotic plaque 
stability in apolipoprotein E-deficient mice fed a high-fat diet. 
Potentially, these effects of EGCG were mediated through 
reduction of MMP and EMMPRIN expression levels and 
suppression of inflammatory responses. Our results indicate 
that EGCG might be a novel therapeutic agent for stabilising 
atherosclerotic plaques. In other studies the consumption of 
green tea has been associated with a reduced risk of AMI. Our 
findings may help to better understand the protective function 
of green tea against AMI in human epidemiological studies.
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WHAT IS NEW?
The rupture of unstable atherosclerotic plaque is the main underlying cause of acute coronary syndrome. Currently, the 
most appropriate therapeutic approach for preventing acute coronary events is to modify the atherosclerotic plaque 
composition rather than bypass the lesion or reduce stenosis by using mechanical interventions. In this work, we evalu-
ated the effect and underlying molecular mechanisms of the green tea polyphenol epigallocatechin-3-gallate (EGCG) on 
atherosclerotic plaque stability in apolipoprotein E-deficient mice. To our best knowledge, we were the first to show that 
EGCG could increase atherosclerotic plaque stability by reducing matrix metalloproteinase expression levels and sup-
pressing inflammatory responses. Our findings provide a new insight into the pharmacological role of EGCG in stabilising 
atherosclerotic plaques.
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